Argos Therapeutics Inc. (ARGS) Issues Earnings Results, Beats Estimates By $0.03 EPS
Argos Therapeutics Inc. (NASDAQ:ARGS) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03.
Argos Therapeutics (NASDAQ:ARGS) opened at 4.80 on Monday. Argos Therapeutics has a one year low of $1.61 and a one year high of $13.97. The firm’s market cap is $197.74 million. The firm’s 50-day moving average price is $4.57 and its 200 day moving average price is $5.36.
A number of equities analysts recently commented on the company. Zacks Investment Research downgraded Argos Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 11th. FBR & Co dropped their price objective on Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Thursday, August 11th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Argos Therapeutics currently has a consensus rating of “Buy” and an average target price of $11.50.
In other Argos Therapeutics news, major shareholder International S. Pharmstandard acquired 5,580 shares of the business’s stock in a transaction dated Monday, September 19th. The shares were acquired at an average price of $4.76 per share, for a total transaction of $26,560.80. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder International S. Pharmstandard acquired 67,371 shares of the business’s stock in a transaction dated Wednesday, August 24th. The shares were acquired at an average price of $4.52 per share, for a total transaction of $304,516.92. The disclosure for this purchase can be found here. Insiders own 61.64% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in ARGS. Schwab Charles Investment Management Inc. acquired a new position in Argos Therapeutics during the second quarter valued at $137,000. California State Teachers Retirement System acquired a new position in Argos Therapeutics during the second quarter valued at $137,000. KCG Holdings Inc. acquired a new position in Argos Therapeutics during the second quarter valued at $163,000. BlackRock Investment Management LLC boosted its position in Argos Therapeutics by 2,162.3% in the second quarter. BlackRock Investment Management LLC now owns 39,567 shares of the biopharmaceutical company’s stock valued at $243,000 after buying an additional 37,818 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in Argos Therapeutics by 13.8% in the third quarter. Bank of New York Mellon Corp now owns 59,430 shares of the biopharmaceutical company’s stock valued at $295,000 after buying an additional 7,215 shares during the period. Institutional investors and hedge funds own 13.87% of the company’s stock.
About Argos Therapeutics
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Stock Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related stocks with our FREE daily email newsletter.